Results 131 to 140 of about 86,629 (276)
eJHaem, Volume 7, Issue 1, February 2026.ABSTRACT Secondary plasma cell leukemia (sPCL) is a rare, aggressive manifestation of multiple myeloma (MM). We report a 75‐year‐old Japanese man with anemia as the chief complaint and IgG‐λ MM that rapidly progressed to sPCL. Whole genome sequencing using Canopy revealed a major clone with a monoallelic TP53 mutation.
Tomotaka Suzuki +4 more
wiley +1 more source
The Effect of Olaparib and Bortezomib Combination Treatment on Ovarian Cancer Cell Lines
, 2020 Çağlar Berkel +5 more
openalex +2 more sources
Efficacy and safety of bortezomib with dexamethasone regimen in elderly newly diagnosed multiple myeloma patients with co-morbidities [PDF]
, 2016 Bortezomib-based induction therapies have shown to increase complete response rates and are used as an upfront therapy for newly diagnosed multiple myeloma patients.
Lee, Saem
core +1 more source
Figure S1 from Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues <i>In Vivo</i> [PDF]
, 2023 Yuezhen Xue +8 more
openalex +1 more source
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL [PDF]
, 2008 Adrian C. Newland +61 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah +8 more
wiley +1 more source
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma [PDF]
, 2012 Alessandra Romano +10 more
openalex +1 more source
Multiple Myeloma : an update on disease biology and therapy [PDF]
, 2004 Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Cook, Rachel J., Dingli, David
core
Cancer Science, Volume 117, Issue 2, Page 407-417, February 2026.We identified a novel mechanism of resistance to histone deacetylase inhibitors (HDACi) in cutaneous T‐cell lymphoma (CTCL), mediated by NF‐κB activation. This finding highlights NF‐κB as a potential therapeutic target for overcoming HDACi resistance in CTCL.
Yuto Takahashi +10 more
wiley +1 more source